Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of “Hold” from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have been assigned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $12.80.

Several brokerages have recently issued reports on IMRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of Immuneering in a report on Monday. Chardan Capital reissued a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research note on Wednesday, January 8th. Finally, Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th.

Immuneering Trading Down 2.6 %

Shares of IMRX stock opened at $1.90 on Thursday. Immuneering has a 12-month low of $1.00 and a 12-month high of $7.68. The stock’s 50-day moving average price is $2.05 and its 200-day moving average price is $1.79. The stock has a market capitalization of $59.00 million, a price-to-earnings ratio of -0.96 and a beta of -0.34.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Marshall Wace LLP bought a new position in shares of Immuneering during the second quarter valued at approximately $492,000. Renaissance Technologies LLC bought a new position in shares of Immuneering during the second quarter valued at approximately $447,000. HighTower Advisors LLC grew its stake in shares of Immuneering by 21.4% during the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after buying an additional 9,400 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Immuneering during the second quarter valued at approximately $67,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Immuneering during the second quarter valued at approximately $44,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.